Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

1998331 citationsJournal Article

Authors

R. A. Rudick · Multiple Sclerosis Foundation

Nancy A. Simonian · Multiple Sclerosis Foundation

Jehan Alam · Multiple Sclerosis Foundation

M. Campion · Multiple Sclerosis Foundation

J. O. Scaramucci · Multiple Sclerosis Foundation

W. E. Jones · Multiple Sclerosis Foundation

Michael E. Coats

Abstract

NAB directed against IFN-beta have in vivo biological consequences in patients with MS. The frequency with which MS patients develop NAB against IFN-beta is significantly greater with IFN-beta-1b therapy compared with IFN-beta-1a therapy. Treatment decisions in MS patients treated with IFN-beta should take into account development of NAB.

Topics & Keywords

Cytokine Signaling Pathways and Interactions Viral Infections and Immunology Research interferon and immune responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 50, Issue 5, pp. 1266-1272

DOI: 10.1212/wnl.50.5.1266

Field-Weighted Citation Impact: 7.76